Montanaro Asset Management Ltd Sells 47,100 Shares of Bruker Corporation $BRKR

Montanaro Asset Management Ltd cut its stake in Bruker Corporation (NASDAQ:BRKR) by 21.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 173,500 shares of the medical research company’s stock after selling 47,100 shares during the quarter. Bruker accounts for about 2.3% of Montanaro Asset Management Ltd’s portfolio, making the stock its 22nd biggest position. Montanaro Asset Management Ltd’s holdings in Bruker were worth $8,174,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Becker Capital Management Inc. raised its position in Bruker by 606.8% in the 3rd quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock valued at $9,800,000 after buying an additional 258,545 shares during the last quarter. DNB Asset Management AS boosted its holdings in Bruker by 40.5% during the 3rd quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock worth $4,654,000 after acquiring an additional 41,289 shares during the last quarter. Aquatic Capital Management LLC grew its stake in shares of Bruker by 120.3% in the 3rd quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock worth $11,358,000 after acquiring an additional 190,883 shares in the last quarter. Callodine Capital Management LP purchased a new stake in shares of Bruker in the third quarter valued at about $1,105,000. Finally, Natixis Advisors LLC raised its holdings in shares of Bruker by 31.1% in the third quarter. Natixis Advisors LLC now owns 627,672 shares of the medical research company’s stock valued at $20,394,000 after purchasing an additional 148,915 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of recent analyst reports. Wolfe Research assumed coverage on shares of Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating for the company. Barclays upped their target price on Bruker from $45.00 to $53.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. TD Cowen lifted their price target on Bruker from $43.00 to $45.00 and gave the stock a “hold” rating in a report on Thursday, May 7th. Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, June 3rd. Finally, Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Bruker currently has a consensus rating of “Hold” and an average target price of $51.31.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is owned by corporate insiders.

Bruker Stock Performance

Shares of BRKR stock opened at $57.23 on Friday. The company has a 50 day moving average of $46.54 and a 200-day moving average of $44.14. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.54. The firm has a market cap of $8.71 billion, a P/E ratio of -238.46, a PEG ratio of 1.83 and a beta of 1.31.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the previous year, the firm posted $0.47 EPS. Bruker’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be paid a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s payout ratio is presently -83.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.